Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company developing RNA- and protein-based medicines using its Endosomal Escape Vehicle (EEV™) technology. The news flow around Entrada centers on its neuromuscular and ocular pipelines, corporate updates and collaboration activities.
Investors following TRDA news can track detailed updates on the company’s Duchenne muscular dystrophy (DMD) franchise, including the ELEVATE-44-201 and ELEVATE-45-201 global Phase 1/2 multiple ascending dose studies of ENTR-601-44 and ENTR-601-45, and the planned development of ENTR-601-50 and ENTR-601-51. Company announcements describe milestones such as first patient dosing, cohort completion, regulatory authorizations in the U.K. and EU, and expectations for future data readouts.
News releases also highlight Entrada’s expansion into ocular and metabolic diseases, including preclinical progress and the nomination of ENTR-801 as the first ocular clinical candidate for Usher syndrome type 2A. Additional coverage includes updates on the VX-670 collaboration for myotonic dystrophy type 1, quarterly financial results furnished via Form 8-K, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), leadership appointments and participation in healthcare and investor conferences.
By reviewing Entrada Therapeutics news, readers can follow how the company reports on its clinical-stage programs, regulatory interactions, financial position and patient-focused initiatives such as the DREAMS Grant Program. This page aggregates press releases and related disclosures so that followers of TRDA can see how the pipeline and corporate activities evolve over time.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced the closing of its initial public offering, successfully selling 9,075,000 shares at $20.00 each, raising approximately $181.5 million. All shares were offered by Entrada. The offering commenced trading on October 29, 2021. Underwriters also hold an option for an additional 1,361,250 shares within 30 days. Goldman Sachs, Cowen, and Evercore acted as joint book-running managers for this offering. The company focuses on innovative Endosomal Escape Vehicle (EEV™) therapeutics targeting previously inaccessible intracellular diseases.
Entrada Therapeutics (Nasdaq: TRDA) has priced its upsized initial public offering (IPO) of 9,075,000 shares at $20.00 per share, aiming for gross proceeds of approximately $181.5 million. This marks a significant step for the biotechnology firm focused on Endosomal Escape Vehicle (EEV™) therapeutics. Trading is set to commence on October 29, 2021, with the offering expected to close on November 2, 2021. The underwriters hold an option for an additional 1,361,250 shares as part of the IPO.